Table 2.
Covariates of csCaP among patients with an ROI ≥ grade 3 (n=825).
| Unadjusted OR (95% CI) |
Adjusted OR (95% CI)1 |
Adjusted OR (95% CI)2 |
|
|---|---|---|---|
| Age at biopsy (per 10 years) | 1.46 (1.21 – 1.76) | 1.40 (1.13 – 1.73) | 1.63 (1.31 – 2.02) |
| PSA (per 5 ng/mL) | 1.24 (1.12 – 1.39) | -- | 1.29 (1.12 – 1.49) |
| Prostate volume (per 10 cc) | 0.76 (0.71 – 0.82) | -- | 0.70 (0.64 – 0.76) |
|
PSA density (per 0.05 ng/mL/cc) |
1.75 (1.58 – 1.94) | 1.33 (1.23 – 1.43) | -- |
| ROI grade | |||
| Grade 3* | -- | -- | -- |
| Grade 4 | 1.91 (1.38 – 2.63) | 1.55 (1.10 – 2.19) | 1.61 (1.14 – 2.27) |
| Grade 5 | 12.80 (7.28 – 22.41) | 7.98 (4.43 – 14.38) | 9.05 (4.96 – 16.50) |
Abbreviations: csCaP – clinically significant prostate cancer; OR – odds ratio; CI – confidence interval; PSA – prostate-specific antigen; ROI – region of interest;
*
reference group;
1
– included covariates for age, PSA density, ROI grade and number of targeted cores and has an area under receiver operating characteristic curve = 0.781;
2
– included covariates for age, PSA, prostate volume, ROI grade and number of targeted cores and has an area under receiver operating characteristic curve = 0.794.